Syncona Limited

Equities

BACT

GG00B8P59C08

Market Closed - London S.E. Other stock markets 23:35:01 11/07/2025 HKT			5-day change	1st Jan Change
96.40 ^GBX	+0.63%		+2.88%	-8.71%

07-02	Syncona Limited Auditor Raises 'Going Concern' Doubt	CI
06-20	UBS cuts Hays and PageGroup to 'neutral'	AN

Syncona Limited, 2025 Earnings Call, Jun 19, 2025

Published on 19/06/2025 at 17:20, updated on 19/06/2025 at 18:35

Presenter Speech
Christopher Hollowood (Executives)

Welcome to Syncona's annual results. As you will have seen, we've also put out a strategic update. This is the outcome of considerable amount of work

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Syncona Limited

Syncona Limited Auditor Raises 'Going Concern' Doubt	07-02	CI
UBS cuts Hays and PageGroup to 'neutral'	06-20	AN
Stocks rise; UK consumer confidence edges up	06-20	AN
Stocks rise; UK consumer confidence edges up	06-20	AN
Stocks rising, UK consumer confidence edges up	06-20	AN
Stocks red, Bank of England votes for rate hold	06-19	AN
Stocks red, Bank of England votes for rate hold	06-19	AN
Syncona Limited, 2025 Earnings Call, Jun 19, 2025	06-19
Syncona plans asset realisation strategy as net asset value falls	06-19	AN
Syncona Plans New Investment Objective, Capital Allocation Policy Changes	06-19	MT
Stocks down in run-up to UK interest rate call	06-19	AN
Syncona To Offer Shareholders Option To Roll Interests Into New Fund	06-19	RE
Syncona Explores Options To Provide Shareholders With Accelerated Cash Returns	06-19	RE
Stocks down after US Fed holds interest rates steady	06-19	AN
UK's Syncona Swings to FY25 Loss; Investment Income Rises	06-19	MT
Earnings Flash (SYNC.L) SYNCONA Posts Fiscal H1 Loss GBX-22.48	06-19	MT
Syncona Limited Reports Earnings Results for the Full Year Ended March 31, 2025	06-19	CI
Syncona investee Spur reports "encouraging" drug trial data	05-15	AN
Syncona's Beacon Therapeutics receives positive data for XLRP therapy	05-07	AN
Syncona Reports Positive Phase II Dawn Trial Results From Beacon Therapeutics	05-07	RE
Jefferies Upgrades Syncona to Buy	04-24	MT
Syncona's Portfolio Company Mosaic Therapeutics Gets Exclusive Rights for Two Clinical-stage Assets	04-24	MT
Syncona sees negative nine-month return despite quarterly rise	02-06	AN
Syncona Posts Quarterly Net Assets Of 1,124.4 Mln Stg	02-06	RE
Syncona Portfolio Company Achilles Therapeutics to Pursue Voluntary Liquidation	02-05	MT